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Introduction
The use of illicit drugs affects every region of the United States, 
but most of our information about drug use comes from large 
urban areas [1]. This is true despite two decades of increasingly 
visible rural drug use and its related harms [2, 3]. While once 
restricted to southern California, methamphetamine has had 
its largest impacts in rural states such as Oklahoma, Iowa, and 
Missouri [4]. More recently, Nebraska has joined this list, with 
increasing evidence of following in its neighbor’s footsteps. The 
most recent Centers for Disease Control and Prevention data 
for Nebraska reveal that substance abuse treatment rates for 
prescription opiate use in 2010 was seven times what it was a 
decade earlier, and opiate-related overdose deaths in Nebraska 
are rapidly approaching the number of deaths due to automobile 
accidents [5]. In neighboring Missouri, overdose deaths have 
exceeded automobile deaths for several years [5]. 
Understanding and preventing health-related harms arising 
from drug use is complex [6, 7]. Years of addiction studies point 
to multifactorial causes for drug abuse, ranging from altered 
neurological function [8], behavioral factors [9, 10] and psycho-
social determinants [11], all operating in complex feedback 
loops. Complicating this are the physical, social, and emotional 
effects of blood born infections such as HIV, hepatitis B and C 
and tuberculosis, as well as a longer list of sexually transmitted 
infections frequently contracted in the context of drug use [12]. 
Although many human-system/virus-system interactions are 
now understood [13], how these are embedded in specific social 
contexts often remains unknown [14]. 
The few studies of rural drug use that exist show marked 
differences in rural versus urban drug users across demographic 
variables such as age or gender [15, 16] and large discrepancies 
in both the contexts of drug use and patterns of drug-related 
health consequences [17-19]. Other less direct disparities include 
differing social stressors, lower overall health levels and health 
care access, a dearth of substance use treatment facilities [20], 
unstable incomes, sparse social networks, and continuing high 
levels of social stigma around drug use and its related infections 
[21]. All of these mark rural drug use as vastly different from use 
in urban areas. Despite a small number of important exceptions 
[15, 18, 20], the urgent challenge of understanding drug use in 
rural settings is significantly under-examined.
The Problem: The United States’ relationship with drugs is 
woven into our national history [22], from tobacco and rum to 
coffee and stimulant-laced drinks, to the use of performance 
enhancing drugs in our national pastime. Further, moral, health, 
economic, and psychological questions around drugs have 
been continually raised and disputed. This consistency does not 
reflect stasis, however. The nature and challenge of drug use 
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continues to change rapidly [23], evolving in location and time 
in reaction to enforcement and education that would curtail use 
and driven forward by consumer demand and high profits [24]. 
Because much of this demand (and profit) is rooted in personal 
addiction, debates about drug use invoke individual and ethical 
dimensions not associated with other health issues. Recent 
findings on rising rates of white male mortality, in part due to the 
increasing numbers of drug-related deaths, has once again raised 
the question of America’s relationship with substance abuse [25] 
and drugs as they reflect or contribute to national moral decline 
[26-30].
Beneath the public furor, however, the health sciences have 
made considerable progress in understanding the etiology of 
drug use and in uncovering the link between drug use and its 
myriad associated harms. To name only a few areas of progress, 
the last three decades have seen remarkable advances in the 
neurochemistry of drug effects, the virology of pathogens whose 
spread is often rooted in drug use [13], the understanding of social 
determinants of drug initiation [31] and clinical approaches to 
drug cessation. Researchers now speak openly and optimistically 
about an HIV vaccine and a cure for AIDS. Safer and more 
reliable forms of opiate inhibitors are emerging every year and 
as the National Institute on Drug Abuse (NIDA) points out, drug 
treatment effectiveness is now on par with the success rates of 
treatments for diabetes and asthma [32]. 
However, this promising scientific news has not always translated 
to better health outcomes. An outbreak of HIV infection in 
southern Indiana in 2015 revealed surprisingly widespread rural 
drug injection [33]. Current estimates of this outbreak are that 
40 percent of the local network of people who inject drugs were 
infected in less than four months, a scenario not witnessed in 
urban areas since the early 1980s [33, 34]. The risks go beyond 
HIV and Clark County, Indiana, where the majority of cases 
were located. A medical state of emergency was declared in 
neighboring Madison County based on a high prevalence of 
hepatitis C virus (HCV) infection discovered in the process of 
understanding the HIV outbreak [34]. 
Nationally, overdose-related deaths and rates of opiate addiction 
in the United States are once again near record highs [35], a 
situation that Department of Health and Human Services (DHHS) 
Assistant Secretary Richard Frank recently identified as a top 
priority for the Administration and DHHS as a whole [36]. Even 
progress in slowing the use of cocaine cannot mask the immense 
growth in the use of other stimulants such as methamphetamine 
[37]. Today, the diversion of prescription and over-the-counter 
medicines into the illicit drug market is more prominent than at 
any time since regulation began [38]. 
These issues are exacerbated by changes in use patterns that 
have seen a dramatic increase in the use of illicit drugs in rural 
and sub-urban areas [39]—a change that (perhaps relatedly) 
locates problems of addiction and drug-related harms in those 
regions where overall health care infrastructure is struggling to 
remain viable. As a result, and in ways not seen before, rural drug 
use has come to urgent national attention. Data on rural drug 
use and its harms justify this attention. Methamphetamine use 
in Nebraska, Oklahoma, Iowa, and Missouri now rivals any region 
in the US [4]. Substance abuse treatment needs in rural states 
dwarf available services [5], and overdose rates in rural states in 
the Central Plains exceed 30 deaths per 10,000 residents in some 
rural counties [40]. Arrest data for cocaine, methamphetamine, 
or heroin possession in rural counties in the region are similar to 
urban zones with similar patterns of drug use such as Maricopa 
County Arizona, and Dallas, Texas [41]. 
Comparisons of rural to urban drug use within Nebraska show 
that rural users start using drugs at a younger age, are more likely 
to use and sell methamphetamine, and use non-marijuana illicit 
drugs at a higher rate than their urban counterparts [16, 42]. Their 
methods of use are more risky as well. Between 40 and 50 percent 
of rural methamphetamine users in Nebraska prefer injection-
based use, nearly twice the urban rate and a similar ratio was 
found for lifetime rates of methamphetamine-related psychosis 
[16, 43]. Daily count methadone use in Nebraska in 2012 was four 
times the rate of 2008 and overall estimates suggest that only 8.6 
percent of illicit drug-dependent individuals received treatment 
during 2012 [43]. In all, 3,594 Nebraskans and 8,131 Iowans were 
admitted for treatment for cocaine, methamphetamine, and 
opiate abuse in 2013, with methamphetamine by far the most 
common. 
Like rural Indiana prior to the 2015 outbreak, rates of HIV are 
low in Nebraska, Iowa, and Kansas. However, risk is high. All of 
these states have highly restrictive syringe access laws [44-46] 
and high treatment deficits [47, 48]. The current treatment need-
to-capacity ratio for opioid addiction in Nebraska is nearly 6:1, 
ranking third worst in the United States behind Arkansas and 
South Dakota (each roughly 7:1) and well behind treatment 
capacity in Connecticut, Massachusetts, and New York, where 
ratios are roughly 1:1 [49]. Together, these factors foster 
significant vulnerability to outbreaks like that seen in Indiana and 
in other rural states [50]. While little surveillance information is 
available for rural areas in the Central Plains, data from regions 
with similar use patterns suggest HCV rates of 40 to 50 percent 
among rural injectors [51-53]. This marks both a hidden precursor 
to the HIV risk made possible by current drug use patterns and a 
serious health crisis in the making.
To address this issue, we need to recognize that clear differences 
exist for rural drug use that make most urban intervention 
programs ineffective. These differences include: 1) the settings 
in which drug use takes place (i.e., social, moral, economic, 
geographical, and environmental contexts); 2) the patterns of 
use and demographics of rural drug users; and 3) the conditions 
and capacities for treatment, intervention, and general care. 
Rural Contexts and Drug Use: Elevated levels of behavioral risk 
for residents of rural areas has been recognized among youth 
[54] and adults [39, 55], although it is also widely recognized 
that data on rural risk remain uneven and insufficient [56]. 
Efforts to understand geographical differences as they influence 
drug-related risks point to a range of “social ecological” factors 
underlying these differences [57, 58]. For example, according to 
Keyes and colleagues [59], the concentration of opiate abuse in 
rural areas is tied to general structural factors that differentiate 
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rural areas from cities, including: 1) higher rates of opioid 
prescription, 2) youth outmigration, 3) larger kinship networks 
that facilitate informal drug trafficking, and 4) more economic 
stress. 
Other approaches note macro-level social structural factors 
(e.g. marked differences in prisoner re-entry outcomes) for rural 
areas [60] or differences in rural drug policing [61]. Still others 
point to radically different racial [62, 63] and economic dynamics 
[64] related to rural use and risk patterns—factors that require 
different treatment and intervention strategies. However, not all 
research takes the urban/rural divide as paramount. Research 
on rural methamphetamine use points to the importance of 
local social contexts in creating micro-locational differences 
within rural areas [65], and research on rural cocaine use 
finds significant population level differences between users of 
different stimulants and their respective risk profiles [62]. Some 
recent evidence even looks at genetic-environment interactions 
and how these affect substance use susceptibility in rural 
areas [66, 67]. These approaches could also shed light on rural 
concentrations of drug use from genetic ‘founder effects.’ Such 
findings point to an important consideration—that the causes 
and implications of rural drug use are highly variegated and may 
be as different from one region to another, or even one county to 
another, as they are from generalized urban trends.
Rural Patterns of Drug Use and Demographics of Rural Users: 
When we shift the focus to rural drug users themselves, there 
is again evidence of systematic differences between urban and 
rural areas, including who uses drugs and how [23, 68]. In a wide 
ranging series of studies in Appalachia, Havens and colleagues 
found marked differences between rural and urban drug users 
(mainly users of prescription opiates) in transitions from first 
use to first injection [17], patterns of initiation of opioids and 
polysubstance use [15, 69], gender propensities [70], and HCV 
infection [71], even while patterns of non-fatal overdose were 
similar [72]. Others have found significant rural/urban differences 
for methamphetamine users [65]. In Nebraska, Kansas, and Iowa, 
treatment admissions for methamphetamine are nearly equal 
for men and women [73], a startling contrast with other drugs 
and other regions. According to the Treatment Episodes Data Set 
(TEDS 2013), in Nebraska, one third of drug treatment admissions 
were for stimulants, and amphetamines were second only to 
alcohol in total treatment admissions [47]. Grant and colleagues 
found that rural methamphetamine users in the state were nearly 
twice as likely to only inject as their urban counterparts were 
(37.2 percent versus 20.2 percent) [16]. This risk profile implies 
radically different potential for HIV and related harms should 
the virus enter these communities. Other harms have already 
taken place: in the same report, Grant and colleagues found that 
lifetime prevalence for meth-related psychosis was much higher 
for rural (44.9 percent) than urban (28.7 percent) individuals, 
despite similarities across all other mental health areas [74].
Research on factors influencing user differences within rural 
areas has focused on many of the same issues that differentiate 
use among urban populations. Meyers found that adolescent 
risk and support factors for stimulant users differed along 
racial lines [75, 76], while Pope found differences for this group 
were (also) patterned by gender [77]. In both cases, similarities 
between urban and rural drug users were clear. These results 
point to an important conclusion—rural users require special 
consideration for multiple reasons, including decidedly higher 
rates of methamphetamine use, a higher proportion of users 
preferring injection, and a user population that is younger and 
riskier than urban counterparts [51, 78]. This conclusion holds 
true regardless of whether greater differences exist between 
urban and rural drug use, or within rural areas themselves,
Rural Capacities for Treatment, Intervention, and Care: Several 
of the above issues contribute to low treatment success rates 
in rural areas. In looking at differences within rural areas, Oser 
and Harp discovered that cultural differences between home and 
treatment venues played a large role in rural treatment outcomes 
[79], findings echoed by McMaster for female methamphetamine 
users [80]. Jackson and Shannon, on the other hand, noted few 
differences in treatment seeking attitudes in rural versus urban 
pregnant women [81]. Rather, in their view, and in the view of 
others, these outcomes for rural treatment seekers may simply 
reflect a shrinking rural health care infrastructure [21, 64] and 
decades of general mortality differences across the full continuum 
of rural settings [82]. There are reasons to suspect this is the case, 
including a documented lack of available substance use disorder 
treatment facilities [83] and drug education programs [84] in 
rural counties. However, these may be only part of the problem, 
as the treatment needs caused by drug use often go beyond 
the actual user, affecting family, community, and environment 
[85]. These findings point to rural conditions that require specific 
attention to regional issues and differences within rural drug 
using populations. At the same time, we must keep in mind the 
clear evidence that larger structural features distinguish rural 
from urban zones, including differences in care.
In the United States, drug use and its associated health risks have 
traditionally been considered an urban problem. For example, 
the Centers for Disease Control and Prevention (CDC)’s National 
HIV Behavioral Surveillance (NHBS) Program on Injection Drug 
Use focuses entirely on the nation’s 25 largest urban areas, 
performing extensive surveillance testing among drug using 
populations in each of these cities every three years. In 
contrast, drug-related disease surveillance in non-urban 
zones is largely restricted to local law enforcement programs. 
In many rural areas, non-prison surveillance is non-existent. 
In the past, this emphasis on urban drug use has been justified 
by low rates of drug-related health impacts in non-urban zones. 
However, the evidence of the last five years shows that this is no 
longer the case.
Discussion
Rural injection drug use and its related harms have come to 
national attention at the same time that drug use in the United 
States has undergone a radical reformulation. New clusters of 
prescription opiate users (23), significant numbers of whom 
transition to heroin and the near ubiquity of methamphetamine 
abuse across rural parts of the country [86] have transformed 
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the national health landscape. Both of these phenomena have 
significantly impacted the Central Plains, a region one recent 
author refers to as “Methland” (22) for the sheer scope of use 
and for its intense impact in a quickly changing rural economic 
landscape. The harms associated with the use of these drugs 
goes beyond the more well-known viruses, with implications 
for sexually transmitted infections contracted in the context of 
drug use [87], mental health problems [88], and other social and 
family harms that ripple out from personal centers of addiction 
[89] (Table 1).
Despite timely and pressing challenges related to rural drug 
use, there are crucial limitations in the current state of research 
surrounding this issue. These challenges must be addressed if we 
hope to impact rural drug use. In general, the need for reliable 
physical, contextual and cognitive data related to the onset and 
desistance of drug use (and behaviors associated with drug use 
harms) is particularly critical for research on rural illicit drugs 
users [90]. Indeed, a significant amount of what we know about 
drug use in urban areas is based on successful, long-term cohort 
studies [90, 91], some of which continue today such as ALIVE [92], 
MIX [93] and VIDUS [94]. However, no rural equivalent currently 
exists and past rural studies have focused mainly on Appalachia [18]. 
When we look at the 32 counties in eastern Nebraska, western 
Iowa, and northern Kansas, we get a sense of the immensity of 
the challenge. By scaling up [95-97] drug-related (non-marijuana) 
arrest data from the Department of Justice's Uniform Crime 
Reporting Program (UCRP; [77]) and hospitalization data from 
the Substance Abuse and Mental Health Services Administration 
(SAMHSA; [78]), we can estimate the size of the drug using 
population in these counties to be ~20,000 individuals (which is ~ 
2.7 percent of the counties’ population of ~ 740,000). This figure 
is commensurate with national prevalence estimates of drug use 
as a percentage of total population [79]. 
While research is needed, immediate solutions to the health risks 
posed by rural drug use are available. Modern day harm reduction 
points to three basic means for minimizing the personal and 
social risks associated with drug use, especially injection drug use 
preventative strategy. This startlingly contradictory position was 
underwritten by entrenched (and essentially irrational) opinions 
about syringe exchange programs—namely, the idea that making 
clean needles available in exchange for dirty ones somehow 
encourages drug use among those not already using drugs, or 
that it increases the level of drug use among those already using. 
This has been shown repeatedly and uniformly to be false in both 
cases [98]. To be clear, there is no evidence in three decades of 
research to suggest either assumption, yet it governs policy in 
nearly half of the states in the US, and nearly all states in the 
Central Plains. This is clearly one of area of public health where 
rational, data-driven outcomes have yet to be adopted in public 
policy arenas, and thus an area where immediate progress could 
be made that would save lives and lower treatment costs, even 
while it protects the wider non-using public from potentially 
dangerous outbreaks of HIV or hepatitis C. Temporarily closing 
the barn door long after the horse has left, as was done in Indiana, 
is unlikely to prevent HIV and hepatitis C outbreaks in places like 
Nebraska, Missouri, Kansas, Oklahoma or Iowa and much of the 
Central and Northern Plains [99].
Opiate substitution treatment: Treatment of opiate addiction has 
included opiate substitution for more than five decades. Among 
the earlier methods was methadone treatment, an opiate that 
produces less of a “high” that is used in measured and medically 
supervised program lessen the effects of heroin or opiate 
withdrawal. Its effectiveness was debated for years, but recent 
retrospective reviews have found that methadone substitution 
treatment was highly effective not just in treating addiction, 
but in lowering on-going risk for infection during the treatment 
period and beyond [100]. 
New treatments using substitution drugs such as buprenorphine 
have proven even more effective than methadone, and have 
longer lasting success rates. Buprenorphine is a partial opiate 
agonist, meaning that it bonds to neurological receptors in the 
brain in a way that is similar to opium (or heroin or a range of 
opiate-based prescription pain killers), but does not produce the 
same effects as opiates (i.e., the opiate delirium experienced as a 
“high”) [100]. It is thus highly effective in staving off withdrawal 
symptoms without fulfilling the psychological need for escape. 
By lessening withdrawal effects, buprenorphine allows the user 
to gradually reduce use and “ease off” of the drug, normally 
while receiving addiction therapy aimed at understanding and 
lessening the causes of psychological addiction. By allowing 
the latter (psychological addiction) to be treated without the 
experience of withdrawal (physiological addiction), the user 
stands a greater chance of successfully confronting those issues 
that inspired drug use/initiation in the past. 
Despite these successes, buprenorphine treatment is very rare 
in the Midwest and Central Plains. Because treatment takes 
place in a doctor’s office and under medical supervision, the 
availability of treatment is dependent on sufficient numbers of 
doctors who are willing to participate. Arkansas, North Dakota 
and Nebraska rank worst in the US in terms of the ratio of opiate 
addicts to buprenorphine prescribing doctors. This is partly due 
to the scope of the opiate addiction problem in these states, 
and partly due to lack of rural medical infrastructure. In some 
ways, the lack of buprenorphine prescribing doctors reflects the 
general lack of medical services in rural areas, but in the situation 
is exaggerated by the stigma attached to drug use and addiction. 
This is particularly troubling because in these states, opiate 
addiction is increasingly a rural problem.
This too is a solvable problem, but one that currently lacks political 
attention. By allowing and promoting buprenorphine services in 
existing rural facilities, successful treatment for growing opiate 
Number of countries 32
Population of countries (P) 740,705
Arrests related to drugs (UCRP) 978
ER admissions for drug use (SAMHSA) 3.050
Est. drug user pop. size (5% arrest rate) 19,560
Est. drug user pop. size (15% ER rate) 20,333
Drug user pop. size as percentage of P 2.7%
Table 1 The scope of illicil drug use in 32 contagious countries of 
eastern Nebraska, Western lowa and northern Kansas.
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addiction in the region could be expanded dramatically in the 
Central Plains. Given that the treatment is covered by virtually 
all public and private forms of insurance, the cost to these states, 
after the initial training and implementation, would be minimal—
and the savings in lost productivity time, emergency room visits, 
and general public risk for drug use related diseases would be 
substantial.
Naloxone: Where buprenorphine is a partial opiate agonist, 
naloxone (often known under the commercial name of Narcan) 
is an opiate antagonist. This means that it operates by blocking 
the attachments of opium to neurological receptors. In effect, 
naloxone prevents opium from having an effect on the brain. For 
this reason, it is often used in emergency situations to reverse an 
overdose. 
As discussed above, drug overdose rates in the Central Plains have 
grown dramatically over the last decade. Missouri, Oklahoma and 
Wyoming have rates of overdose nearly double the rates of New 
York, California, Texas, or Virginia and nearly double the rates of 
Eastern rural states that have receive considerably more public 
attention such as Vermont. Notably, some states in the Central 
Plains still do not make naloxone available to the public, nor 
have they passed “Good Samaritan” laws protecting bystanders 
who report overdose incidents to emergency services, or who 
administer naloxone to someone who has overdosed. 
Unlike syringe exchange or buprenorphine availability, 
considerable progress has been made in this area, however. 
Central Plains states with high levels of overdose have taken 
action to make overdose deaths less likely by making naloxone 
more available and its use in an emergency more protected. 
Holdouts continue, though, including Missouri, Kansas, South 
Dakota, Iowa, Minnesota and Wyoming. This is difficult to 
understand, other than to point out the overall punitive attitude 
toward addicts in these states. Again, there now exist easy and 
low cost means to mitigate the relationship between drug use 
and overdose death, held back only by a seeming desire to punish 
addicts for their addiction.
Taken together, these three inexpensive and cost effective 
programs could greatly reduce the disease risk of injection drug 
use, facilitate addiction recovery, and reverse the rising rate of 
accidental death associated with overdose. All of these programs 
have been employed in other regions with considerable success, 
and with none of the feared side-effects of increased drug use. 
The lesson that we need to recognize in Nebraska and the Central 
Plains is that data driven means for dealing with rising rural drug 
use in our region are available, and acting only after the problem 
can no longer be ignored ensures that these means will cost more 
and be more widely needed. In short, the time to act is now.
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